目的 构建一套充分反映非处方药（OTC）特点的综合价值评价指标体系，为OTC遴选、监管、流通使用等决策提供结构清晰、操作性强的多维决策工具，推动行业高质量发展。方法 通过文献研究及德尔菲法建立指标体系，采用层次分析法确定指标权重。结果 经过2轮德尔菲专家函询后，最终确定OTC综合价值评价指标体系，包含6个一级维度、16个一级指标以及27个二级指标。Kendall协调系数均大于0.4，χ²检验P值均小于0.001，结果具有较好的一致性。利用层次分析法对OTC综合价值评价指标体系的各级指标进行权重赋值，各判断矩阵均通过一致性检验。结论 构建的OTC综合价值评价指标体系具有较高的权威性和科学性，可为监管部门、医疗机构及消费者提供决策依据。

Objective To establish a comprehensive value evaluation index system that fully reflects the characteristics of over-thecounter(OTC) drugs, providing a clear and operationally feasible multi-dimensional decision-making tool for OTC drug selection, regulation, distribution, and use, thereby promoting high-quality development in the industry. Methods The indicator system was established through literature research, Delphi method, and the weights of the indicators were determined using the analytic hierarchy process. Results After two rounds of Delphi expert consultations, the final comprehensive value assessment indicator system for OTC drugs was established, comprising six primary dimensions, 16 primary indicators, and 27 secondary indicators. Kendall's coefficient of concordance was greater than 0.4 for all indicators, and the χ² test P-values were all less than 0.001, indicating good consistency in the results. The Analytic Hierarchy Process was used to assign weights to the indicators at all levels of the comprehensive value assessment indicator system for OTC drugs, and all judgment matrices passed the consistency test. Conclusion The comprehensive value assessment indicator system for OTC drugs constructed in this study has high authority and scientific rigor, providing a basis for decision-making for regulatory authorities, medical institutions, and consumers.

R95

国家卫生健康委卫生发展研究中心科研课题(XMBH-202407-078-03472)